1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalende Worldwide in 2012. WHO web site. Accessed 2011].
http://globocan.iarc.fr/Default.aspx.
2. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-2899. 15860847.
3. Schwartz JM, Ham JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2003;6:465-472. 14585235.
4. Gudkov AV, Komarova EA. The role of P53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-129. 12563311.
5. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239-253. 21430696.
6. Katz D, Ito E, Liu FF. On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys 2009;73:988-996. 19251086.
7. Banfi A. Principles of radiotherapy. In: Bonnadona G, Robustelli della Cuna G, eds. Handbook of medical oncology. Milano: Masson; Chicago: Year Book Medical; 1988. p. 191-196.
8. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42:994-1003. 16564689.
9. Keng GH, Sundram FX. Radionuclide therapy of hepatocellular carcinoma. Ann Acad Med Singapore 2003;32:518-524. 12968558.
10. Keng GH, Sundram FX, Yu SW, Somanesan S, Premaraj J, Oon CJ, et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates. Ann Acad Med Singapore 2002;31:382-386. 12061301.
11. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nature reviews. Nat Rev Gastroenterol Hepatol 2010;7:41-49. 20051971.
12. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur 2012;15:120-123. 22936505.
14. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev 2004;23:237-257. 15197326.
15. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-221. 2649981.
16. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603. 15286739.
17. Kaino M. Alterations in the tumor supressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 1997;32:40-46. 9058294.
18. Mamede AC, Pires AS, Abrantes AM, Tavares SD, Gonçalves AC, Casalta-Lopes JE, et al. Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies. Nutr Cancer 2012;64:1049-1057. 22974001.
19. Brito AF, Mendes M, Abrantes AM, Tralhão JG, Botelho MF. Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose. Mol Diagn Ther 2014;18:495-504. 24852041.
20. Li J, He M, Shen B, Yuan D, Shao C. Alpha particle-induced bystander effect is mediated by ROS via a p53-dependent SCO2 pathway in hepatoma cells. Int J Radiat Biol 2013;89:1028-1034. 23786650.
22. Jiang Y, Zhou X, Chen X, Yang G, Wang Q, Rao K, et al. Benzo(a) pyrene-induced mitochondrial dysfunction and cell death in p53-null Hep3B cells. Mutat Res 2011;726:75-83. 21911080.
24. Friedman SL, Shaulian E, Littlewood T, Resnitzky D, Oren M. Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 1997;15:63-70. 9233778.
25. Kuo PL. Lin TC, Lin CC. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. Life Sci 2002;71:1879-1892. 12175703.
26. Reiser M, Neumann I, Schmiegel W, Wu PC, Lau JY. Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene. J Hepatol 2000;32:771-782. 10845664.
27. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004;53:519-526. 15004724.
29. Slebos RJ, Resnick MA, Taylor JA. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Res 1998;58:5333-5336. 9850060.
30. Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor.. U.S. Patent No. 4, 393,133. Washington: U.S. Patent and Trademark Office; 1983.
32. Verheij M. Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer Metastasis Rev 2008;27:471-480. 18470482.
33. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer 1999;6:41-44. 10732785.
34. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20:1-15. 16391229.
35. Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, et al. Apoptosis and p53 are not involved in the anti-tumor efficacy of
125I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol 2013;40:471-480. 23522976.
36. Baumann K. Cell death: multitasking p53 promotes necrosis. Nat Rev Mol Cell Biol 2012;13:480-481. 22781904.
37. Andrianantoandro E. p53 Opens the Gates to Necrosis. Sci Signal 2012;5:ec175.
38. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27-33. 7905906.
39. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40. 16430879.
40. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008;7:1875-1884. 18981733.
41. Van Pelt WR, Drzyzga M. Beta radiation shielding with lead and plastic: effect on bremsstrahlung radiation when switching the shielding order. Health Phys 2007;92(2 Suppl):S13-S17. 17228183.